AUDENTES THERAPEUTICS, INC. (a Delaware corporation) [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 11th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”), Cowen and Company, LLC (“Cowen”), Piper Jaffray & Co. (“Piper”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch, Cowen and Piper are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.00001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of [●] additional shares of
INDEMNITY AGREEMENTIndemnity Agreement • July 11th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnity Agreement, dated as of , 2016 is made by and between Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), and , a director, officer or key employee of the Company or one of the Company’s subsidiaries or other service provider who satisfies the definition of Indemnifiable Person set forth below (“Indemnitee”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 11th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (“Company”) and John Gray (“Employee”). This Agreement is effective as of December 18, 2015 (“Effective Date”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 11th, 2016 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (“Company”) and Matthew Patterson (“Employee”). This Agreement is effective as of July 16, 2013 (“Effective Date”).
